Advanced Medical Solutions Group Regulatory News (AMS)

Advanced Medical Solutions Group plc

("AMS", the "Company" or the "Group")

Notice of AGM and Management Change

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, will hold its Annual General Meeting at 11.00 am today at 85 Gresham Street, London, EC2V 7NQ. At the AGM, Chris Meredith, AMS's Chief Executive Officer, will give a short presentation. No new material information will be provided.

AMS also announces today that Mary Tavener intends to retire from the role of Chief Financial Officer and Board Director on 31 December 2018, after 19 years with the Company. At the same time, Eddie Johnson, who has been with AMS for more than six years, and is currently Group Financial Controller, will assume the role of Chief Financial Officer and join the Board.

Commenting on the announcement, Peter Allen, Non-Executive Chairman of AMS, said: "I would like to thank Mary for her 19 years of dedicated and outstanding service to AMS. In her time with the Group, she has been integral to our listing on AIM, several acquisitions and this has culminated in AMS growing for 13 consecutive years. At the same time, I would also like to congratulate Eddie on his forthcoming appointment as Chief Financial Officer and we look forward to welcoming him to the Board in due course."

Edward ("Eddie") Johnson, 46, is not currently, nor has he been in the last five years, a director or partner in any company or partnership respectively. Other than as set out in this announcement, there are no further disclosures required under Schedule Two, paragraph (g) of the AIM Rules for Companies.

- Ends -

For further information, please visit www.admedsol.com or contact:

About Advanced Medical Solutions Group plc - see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands; ActivHeal®, LiquiBand® and RESORBA® as well as supplying under white label.

AMS's products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 75 countries via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Group has approximately 600 employees. For more information, please see www.admedsol.com.